Crescent Biopharma (CBIO) 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA summary

Company strategy and portfolio overview

• Focused on next-generation oncology with IO bispecifics and ADCs, leveraging a matrix portfolio approach.

• Four clinical studies across three programs to be initiated this year, setting up for a data-rich 2027.

• Strategic partnership with Kelun-Biotech enables combination studies and global development acceleration.

• Well-capitalized to reach key milestones and execute through 2026.

CR-001 program insights

• CR-001 designed to replicate and improve upon ivonescimab, with higher concentration manufacturing and proprietary modifications.

• ASCEND global phase I trial underway, focusing on multiple solid tumors including lung, GI, and gynecologic cancers.

• Initial data in Q1 2027 will include safety, PK, pharmacodynamics, and anti-tumor activity, especially in non-small cell lung cancer.

• Expansion cohorts will assess combination with standard chemotherapies across tumor types.

ADC and combination strategy

• Integrin beta-6 identified as a high-value ADC target due to tumor-specific expression.

• CR-003, an integrin beta-6 topo ADC, is in phase I/II in China, with global development leveraging Kelun-Biotech data.

• Multiple ADCs, including sac-TMT and PD-L1 topo ADC, are being explored as monotherapies and in combination with CR-001.

• Data from ADC/IO combinations, especially with Kelun’s assets, expected to inform future strategy.